News

Scorpion Capital discloses short position in drugmaker Soleno

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...
Asianet Newsable on MSN4d

Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet

The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema ...

Soleno Therapeutics stock falls after Scorpion Capital short report

Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...

Soleno Therapeutics plunges after short report from Scorpion Capital

Soleno Therapeutics (SLNO) dropped 16% in premarket trading after a new short report from Scorpion Capital. Scorpion Capital ...